|
(P1419) |
Early identification of heart failure patients at the population level - Data from the Hamburg City Health Study |
| |
|
B. Schrage, R. Bei der Kellen, J. Wenzel, J. Nikorowitsch, R. Schnabel, S. Blankenberg, C. Magnussen (Hamburg) |
|
(P1420) |
Relationship of heart failure and diabetes mellitus in patients with atrial fibrillation – Insights from a cohort study of 7,850 patients with long follow-up. |
| |
|
F. Hofer, P. Sulzgruber, M.-P. Winter, C. Gerges, M. Hülsmann, R. Schönbauer, L. Koller, A. Niessner, C. Hengstenberg, T. Zelniker (Wien, AT) |
|
(P1421) |
The SGLT-2 inhibitor empagliflozin reduces tissue sodium content in patients with chronic heart failure |
| |
|
J. Kolwelter, D. Kannenkeril, P. Linz, A. M. Nagel, A. Bosch, K. Striepe, C. Ott, P. Bramlage, M. Uder, S. Achenbach, R. E. Schmieder (Erlangen, Mahlow) |
|
(P1422) |
Sensitivity and specificity of diagnostic methods in patients with assumed infective endocarditis and histopathologically examined valves |
| |
|
C. Schach, J. Li, K. Menhart, L. S. Maier, C. Schmid (Regensburg) |
|
(P1423) |
Cardiac biomarkers as indicators of right ventricular dysfunction and recovery in CTEPH – A cardiac magnetic resonance imaging study |
| |
|
S. Kriechbaum, J.-M. Vietheer, C. Wiedenroth, F. Rudolph, M. Barde, J. S. Wolter, M. Haas, U. Fischer-Rasokat, A. Rolf, C. W. Hamm, E. Mayer, S. Guth, T. Keller, F. Roller, C. Liebetrau, für die Studiengruppen: BioReg, SFB-CRC1213 (Bad Nauheim, Gießen) |
|
(P1424) |
MiRNA profiling as a novel diagnostic tool for identification of patients with inflammatory and/or virally-induced cardiomyopathies |
| |
|
G. Aleshcheva, H. Pietsch, F. Escher, H.-P. Schultheiss (Berlin) |
|
(P1425) |
Diagnosing heart failure with preserved ejection fraction – a comparison of the ESC 2016, the H2FPEF- and the HFA-PEFF diagnostic algorithm |
| |
|
J. Nikorowitsch, R. Bei der Kellen, C. Magnussen, R. Schnabel, S. Blankenberg, J. Wenzel, für die Studiengruppe: HCHS Echo (Hamburg) |
|
(P1426) |
Diagnostic Value of High-Sensitive Troponin for the Prediction of Myocardial Infarction Requiring Revascularization in Acute Heart Failure |
| |
|
J. Ledwoch, A. Schneider, K. Leidgschwendner, J. Kraxenberger, A. Krauth, V. S. Schneider, E. Martens, A. Müller, K.-L. Laugwitz, C. Kupatt (München) |
|
(P1427) |
Sepsis-induced acute heart failure is driven by MEF2D-dependent transcription |
| |
|
R. Schell, F. Alban, C. Haslinger, P. Theis, H. A. Katus, N. Frey, J. Backs (Heidelberg) |
|
(P1428) |
Proteomics for Phenotyping and Risk Stratification in Heart Failure with Preserved Ejection Fraction and Obesity |
| |
|
K.-P. Rommel, K.-P. Kresoja, C. Besler, S. Henger, N. Klöting, P. Büttner, U. Ceglarek, H. Thiele, M. Scholz, M. Blüher, P. Lurz (Leipzig) |
|
(P1429) |
Sodium-glucose cotransporter 2-inhibitors (SGLT2i) improve cardiovascular outcomes in patients with type 2 diabetes mellitus (T2D) |
| |
|
T. Täger, D. Atar, H. A. Katus, N. Frey, H. Fröhlich, L. Frankenstein (Heidelberg; Oslo, NO) |
